Brief: Santhera: Exclusive North America License Agreement With Catalyst For Vamorolone

Santhera Pharmaceuticals Holding AG

19/07/2023 06:03

July 19 (Reuters) - Santhera Pharmaceuticals Holding AG
 SANN.S :
    * SANTHERA ANNOUNCES CLOSING OF EXCLUSIVE NORTH AMERICA
LICENSE
AGREEMENT WITH CATALYST PHARMACEUTICALS FOR VAMOROLONE
    * LICENSE AGREEMENT GRANTS CATALYST COMMERCIALIZATION RIGHTS
IN
NORTH AMERICA (NA) FOR VAMOROLONE IN DUCHENNE MUSCULAR DYSTROPHY
(DMD) AND ALL POTENTIAL FUTURE INDICATIONS FOR A TOTAL
CONSIDERATION TO SANTHERA OF UP TO USD 231 MILLION PLUS ROYALTY
PAYMENTS FROM PRODUCT SALES
    * SUBJECT TO U.S. FDA APPROVAL OF VAMOROLONE IN DMD, A
DECISION
EXPECTED BY OCTOBER 26, 2023 PDUFA DATE, SANTHERA WILL RECEIVE
ANOTHER USD 10 MILLION FROM CATALYST
    * SANTHERA IS ELIGIBLE TO RECEIVE SALES-BASED MILESTONES OF
UP TO
USD 105 MILLION AS WELL AS ROYALTIES ON SALES
    * CATALYST WILL ALSO PAY USD 26 MILLION OF SANTHERA'S
THIRD-PARTY
OBLIGATIONS AT FDA APPROVAL, AND ROYALTY OBLIGATIONS ON
VAMOROLONE SALES IN ALL INDICATIONS IN NA

Source text for Eikon:  ID:nGNEc8ydH5 
Further company coverage:  SANN.S 

 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))